Content area
Abstract
In the same study, one hypertensive subject who received oral doses of 0.3 mg (or 0.004 mg/kg for a 70-kg individual) experienced a change in blood pressure from 183/104 mmHg pre-treatment to 115/68 mmHg post-treatment. The reagent fluid in many COVID-19 rapid antigen home test kits contains sodium azide in concentrations of 0.0125–0.0946%, and personal communication with test kit manufacturers revealed that the reagent fluid volume in these kits is small (0.3–0.625 mL) [1-3]. [...]reagents with sodium azide concentrations less than 0.09–0.095% generally contain extremely low amounts of sodium azide (0.04–0.08 mg), or well below the amount expected to cause transient hypotension in adults. Children may experience serious adverse events after exploratory oral exposures to minimal amounts of the reagent solutions due to their smaller body size and should be monitored closely for hypotension or other sequelae after ingestion of even minute quantities of reagent fluids. Since the onset of hypotension after oral exposure to sodium azide is rapid, prolonged observation is likely unnecessary for individuals who remain asymptomatic after reagent fluid ingestion.